Main Uses of Aglikem

Aglikem is an oral medication primarily used for the management of type 2 diabetes mellitus. It belongs to a class of drugs known as biguanides, which work by improving the way the body handles insulin and glucose.

Blood Sugar Management

The primary role of Aglikem is to help control high blood sugar levels. It achieves this through three main mechanisms:

• Reduction of Glucose Production: It decreases the amount of glucose (sugar) produced by the liver.
• Improved Insulin Sensitivity: It enhances the body's sensitivity to insulin, allowing cells to remove glucose from the blood more effectively.
• Delayed Glucose Absorption: It slows down the absorption of sugar from the intestines during digestion.

Type 2 Diabetes Treatment

Aglikem is specifically indicated for type 2 diabetes, a condition where the body either does not produce enough insulin or cannot properly use the insulin it makes. It is often used when diet and exercise alone are not sufficient to maintain healthy blood sugar levels. It is not used for the treatment of type 1 diabetes.

Potential Benefits

Beyond its primary function of lowering blood glucose, Aglikem offers several clinical benefits for individuals managing type 2 diabetes:

Cardiovascular Health

Effective management of blood sugar levels is a key factor in reducing the long-term risk of cardiovascular complications associated with diabetes, such as heart disease and stroke.

Weight Neutrality

Unlike some other glucose-lowering medications, Aglikem is generally considered weight-neutral, meaning it typically does not cause weight gain. In some cases, it may assist in modest weight loss when combined with appropriate lifestyle changes.

Long-term Complication Prevention

By maintaining blood glucose levels within a target range, Aglikem helps lower the risk of developing chronic diabetes-related issues, including:

• Kidney damage (nephropathy)
• Nerve damage (neuropathy)
• Eye problems (retinopathy)
• Foot and limb complications

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults are eligible under standard labeled conditions. Pediatric patients 10 years of age and older are approved for use of the immediate-release formulation.
Populations for whom use is not recommended	Initiation is not recommended in patients with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min/1.73 m²; use should generally be avoided in patients with clinical evidence of hepatic disease.
Populations for whom use is contraindicated	The medicine is contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73 m²). It is also prohibited for patients with acute or chronic metabolic acidosis and those with a known hypersensitivity to Metformin Hydrochloride.

---

Eligibility Classifications

Category	Classification Statement
Age-related eligibility rules	For geriatric patients (age 65+), renal function must be assessed more frequently. Use of the extended-release form is not established in children younger than 18 years of age.
Eligibility-related restrictions	The medicine must be temporarily discontinued at the time of, or prior to, an iodinated contrast imaging procedure in specific at-risk populations. Similarly, it must be suspended for any surgical procedure requiring restricted fluid intake.

---

Connection to the overall eligibility profile

The eligibility profile for Aglikem is strictly defined by regulatory criteria, with renal function being the primary determinant of approval status. These constraints formally classify who must not use the medicine (contraindicated populations) and who requires conditional or restricted use, as documented by authoritative sources like the FDA and EMA. The rules ensure use is limited to those who can safely clear the medicine from their system, with mandatory, frequent monitoring for elderly patients.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Aglikem (Metformin Hydrochloride) primarily around the risk of Lactic Acidosis and modifications to glycemic control.

Documented Interaction Patterns and Restrictions

Interaction Type	Interacting Agent	Official Regulatory Statement
Timing-Mandated Cessation	Iodinated Contrast Media	Use is restricted due to the documented risk of Lactic Acidosis. Aglikem must be temporarily discontinued at the time of or prior to the procedure and withheld for 48 hours subsequent to the procedure. Reinstitution is restricted until renal function is re-evaluated.
Exposure Modification	Cationic Drugs (e.g., Cimetidine, Ranolazine, Dolutegravir)	These agents are formally documented to increase Metformin plasma concentrations (exposure) by reducing its renal clearance.
Pharmacodynamic	Insulin and Insulin Secretagogues	Co-administration is officially associated with an additive glucose-lowering effect, resulting in an increased risk of Hypoglycemia.
Pharmacodynamic	Drugs that increase blood glucose (e.g., Corticosteroids, Diuretics)	These substances may reduce the intended antihyperglycemic action, officially leading to a loss of glycemic control.
Substance Restriction	Excessive Alcohol Intake	Officially restricted as it is documented to potentiate the effect of Metformin on lactate metabolism, increasing the risk of Lactic Acidosis.

Population-Specific Interaction Notes

Regulatory labels note that the interaction-related risk of Lactic Acidosis is formally increased in geriatric patients (over 65 years of age) due to the greater likelihood of reduced renal function, and in patients with hepatic impairment.

Aglikem (Imeglimin) operates through a novel dual mechanism centered on modulating cellular mitochondrial dysfunction in key metabolic tissues.

1. Modulation of Cellular Bioenergetics

The mechanism’s primary targets are components of the mitochondrial respiratory chain. Aglikem functions as a modulator, inducing a partial inhibition of Complex I while correcting deficient activity in Complex III. This rebalancing of the electron transport chain reduces cellular oxidative stress and modulates the availability of ATP and NAD^+ within the cell.

2. Regulation of Systemic Glucose Dynamics

The intracellular action cascades into two major physiological effects: enhanced glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells, and an improved peripheral insulin sensitivity in tissues like the liver and muscle. This modulation influences both the capacity for insulin release and the responsiveness of tissues to insulin, leading to the suppression of excessive hepatic glucose production (gluconeogenesis) and promotion of increased peripheral glucose uptake.

Aglikem is administered orally and is available as an immediate-release (IR) tablet and an extended-release (ER) tablet. The administration protocol begins with a low starting dose, followed by a gradual titration schedule to establish a stable maintenance level.

The IR formulation is typically started at 500 mg twice daily or 850 mg once daily for adults, with the dose increases usually occurring weekly in 500 mg increments to support patient tolerability. The total daily dose is divided and generally should not exceed 2550 mg. The ER formulation is usually started at 500 mg to 1000 mg taken once daily, with a maximum labeled dose of 2000 mg per day.

All formulations must be taken with meals to support proper absorption and administration. The extended-release tablets must be swallowed whole and must not be cut, crushed, or chewed, as this action compromises the drug’s intended slow-release mechanism. Aglikem is intended for long-term therapy, requiring administration two or three times daily for the IR form or once daily for the ER form.

Administration is subject to constraints based on renal function; for example, use is contraindicated for those with an estimated Glomerular Filtration Rate (eGFR) below 30 mL/min/1.73 m^2. Additionally, temporary discontinuation is required at the time of or prior to iodinated contrast imaging procedures.

Research Evidence / Overview of Studies for Aglikem

This section describes the research that has been conducted on Aglikem and what has been observed so far. It summarizes the findings from clinical trials and other studies, highlighting what is known and what remains uncertain about the compound’s effects on different populations and health measures.

Evidence from Studies in Adults with Type 2 Diabetes Mellitus

Research exploring Aglikem in adults with Type 2 Diabetes Mellitus (T2DM) includes large, well-structured clinical trials (RCTs). These short-term and intermediate-term studies examined how common diabetes markers change over defined time intervals. The trials specifically measured outcomes primarily focusing on levels like HbA1c (a measure of average blood sugar) and fasting glucose, as well as changes in body weight.

Studies observed patterns where the average measurements of these glucose markers differed between the group receiving the compound and the groups receiving placebo or an active comparator drug. These research highlights changes measured during the study period and contributes to understanding symptom patterns.

Evidence from Studies in Pediatric Patients

Studies exploring Aglikem for T2DM in younger populations (specifically patients aged 10 and older) include a limited number of smaller, short-term, placebo-controlled RCTs. Findings were mixed across these studies, and evidence for this age group remains limited and heterogeneous. Reported outcomes were short-term, typically covering only a few months, and were based on relatively small populations compared to the adult trials.

Long-Term Data and Evidence Gaps

Research has explored whether the observed patterns in glucose level measurements are maintained over one year or more. However, the long-term pattern of effect on measured physiological variables and outcomes is not fully established. Limited information is available for a number of patient groups, and certain large-scale, long-term outcomes, such as those related to cardiovascular disease events, are not well characterized by the current body of evidence. Direct comparative evidence against other specific treatments may also be lacking.

Common questions about Aglikem (FAQ)

Q: Does Aglikem interact with alcohol and what is the risk?

Official product information states that excessive alcohol intake is a restriction when using this medicine. This restriction is due to the potential for alcohol to potentiate the effect of the medicine on lactate metabolism. This is associated with an increased risk of a rare but serious metabolic complication called lactic acidosis.

---

Q: What is the main biological way Aglikem works to lower blood sugar?

The medicine works in several ways to help manage blood sugar, as described in official documents. It primarily functions by decreasing the amount of glucose (sugar) produced by the liver. It also helps improve how responsive the body's tissues are to its own naturally occurring insulin, which aids in blood sugar control.

---

Q: Can children take Aglikem?

Regulatory documents indicate that the immediate-release tablet formulation of this medicine is approved for use in pediatric patients who are 10 years of age and older. Official guidelines specify the use of the immediate-release formulation and define a maximum daily dose for this population.

---

Q: If I'm taking the IR tablet, how many times a day do I take it?

Official prescribing information describes starting administration for the immediate-release (IR) tablet as being taken once or twice daily, always with meals. For patients who require higher doses, the medicine may be better tolerated when taken three times a day.

---

Q: How long does it take for Aglikem to start working?

Based on official pharmacokinetic information, the concentration of the medicine in the blood reaches a stable level, known as steady-state, within about 24 to 48 hours when taken as prescribed. The immediate-release form reaches its maximum concentration in the body in approximately one to three hours.

---

Q: Does Aglikem help with weight loss?

The medicine is formally indicated to help improve blood sugar control as part of a regimen that includes diet, exercise, and weight reduction. While clinical studies for this medicine measure changes in body weight, its primary formal indication is for the management of high blood sugar.

---

Q: What should I do if I miss a dose of Aglikem?

Patient counseling information states that the recommended approach is to skip the missed dose and resume the usual schedule with the next dose, avoiding taking two doses on the same day.

The official storage and disposal requirements for Aglikem (Metformin Hydrochloride) are defined by government regulatory documents to ensure product safety and stability.

Official Storage and Disposal Profile

Requirement	Regulatory Statement
Storage Temperature	Store at Controlled Room Temperature (20 C to 25 C), permitting brief excursions up to 30 C.
Protection	Keep the container tightly closed and protect the product from moisture and excessive heat. Do not refrigerate.
Child Safety	Keep this and all medicines out of the sight and reach of children and store the product securely.
Disposal	Disposal of unused or expired product should preferentially utilize an official drug take-back program or authorized collection site. If no take-back option is available, dispose of the medicine in household trash after mixing with an undesirable, sealed substance (e.g., used coffee grounds or cat litter).

Regulatory documents state that the product is stable until the printed expiration date when stored under these specific, controlled conditions. The label prohibits disposal by flushing or pouring into a drain to prevent environmental release.